Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide.

Methods

Etoposide plasma levels were determined by HPLC.

Results

The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses.

Conclusions

The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Abbreviations

AUC0–∞ :

Area under the curve from time zero to infinity

Cmax :

Maximum plasma concentration of drug

Cltot :

Total plasma clearance

HPLC:

High-pressure liquid chromatography

Poct :

Octanol-water partition coefficient

t1/2β :

Beta phase plasma elimination half-time

tr :

Retention time

References

  1. Green JA, Tarpey AW, Warenius HM (1988) Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. Acta Oncol 27:819–822

    CAS  PubMed  Google Scholar 

  2. Hainsworth JD, Greco FA (1995) Etoposide: twenty years later. Ann Oncol 6:325–341

    CAS  PubMed  Google Scholar 

  3. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44:379–382

    CAS  PubMed  Google Scholar 

  4. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953–958

    Article  CAS  PubMed  Google Scholar 

  5. Henwood JM, Brogden RN (1990) Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39:438–490

    CAS  PubMed  Google Scholar 

  6. Holm B, Jensen PB, Sehested M (1996) ICRF-187 rescue in etoposide treatment in vivo. A model targeting high dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38:203–209

    Article  CAS  PubMed  Google Scholar 

  7. Holm B, Sehested M, Jensen PB (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 4:1367–1373

    CAS  PubMed  Google Scholar 

  8. Holthuis JJ, Postmus PE, Van Oort WJ, Hulshoff B, Verleun H, Sleijfer DT, Mulder NH (1986) Pharmacokinetics of high dose etoposide (VP 16-213). Eur J Cancer Clin Oncol 22:1149–1155

    CAS  PubMed  Google Scholar 

  9. Jensen PB, Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54:755–759

    Article  CAS  PubMed  Google Scholar 

  10. Kohl P, Koppler H, Schmidt L, Fritsch HW, Holz J, Pfluger KH, Jungclas H (1992) Pharmacokinetics of high-dose etoposide after short-term infusion. Cancer Chemother Pharmacol 29:316–320

    PubMed  Google Scholar 

  11. Liliemark E, Pettersson B, Peterson C, Liliemark J (1995) High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells. J Chromatogr B Biomed Sci Appl 669:311–317

    Article  CAS  Google Scholar 

  12. Newman EM, Doroshow JH, Forman SJ, Blume KG (1988) Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 43:561–564

    CAS  PubMed  Google Scholar 

  13. Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB (2003) Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 52:167–174

    CAS  PubMed  Google Scholar 

  14. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46:389–393

    Article  CAS  PubMed  Google Scholar 

  15. Swain SM, Whaley F, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333–1340

    CAS  PubMed  Google Scholar 

  16. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318–1332

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Canadian Institutes of Health Research, the Canada Research Chairs program, and a Canada Research Chair in Drug Development for Brian Hasinoff, and grant support for Kenneth Hofland by a H:S Research Council (Denmark). Patricia Schroeder was supported by a Manitoba Health Research Council studentship and a Canadian Institutes of Health Research studentship.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, R3T 2N2, Canada

    Patricia E. Schroeder & Brian B. Hasinoff

  2. Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark

    Kenneth Francis Hofland, Peter Buhl Jensen & Seppo W. Langer

  3. The Finsen Center and Department of Pathology, The National University Hospital, 2100, Copenhagen, Denmark

    Maxwell Sehested

Authors
  1. Patricia E. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Francis Hofland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Buhl Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maxwell Sehested
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seppo W. Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brian B. Hasinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian B. Hasinoff.

Additional information

Patricia Schroeder and Kenneth Hofland contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schroeder, P.E., Hofland, K.F., Jensen, P.B. et al. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother Pharmacol 53, 91–93 (2004). https://doi.org/10.1007/s00280-003-0711-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0711-z

Keywords

Search

Navigation